
CGEM News
Cullinan Therapeutics, Inc.
$9.07
+$0.06(+0.67%)
39
Overall
60
Value
36
Tech
21
Quality
Market Cap
$588.83M
Volume
998.32K
52W Range
$8.23 - $23.19
Target Price
$35.91
CGEM news: the latest Cullinan Therapeutics, Inc. headlines, press releases and market updates, newest first.
Latest CGEM News
- Guggenheim Sticks to Their Buy Rating for Cullinan Management (CGEM)TipRanks Auto-Generated Intelligence Newsdesk · Nov 12, 2026
- Wall Street Analysts Are Bullish on Top Healthcare PicksTipRanks Newsroom · Nov 10, 2026
- Cullinan Reports Positive Velinotamig Lupus Trial Interim DataTipRanks Auto-Generated Newsdesk · Nov 9, 2026
- Wedbush Sticks to Their Buy Rating for Cullinan Management (CGEM)TipRanks Auto-Generated Intelligence Newsdesk · Nov 5, 2026
- Cullinan Shares Updated CLN-049 Phase 1 AML/MDS DataTipRanks Auto-Generated Newsdesk · Nov 4, 2026
- BTIG Reaffirms Their Buy Rating on Cullinan Management (CGEM)TipRanks Auto-Generated Intelligence Newsdesk · Nov 3, 2026
- Cullinan’s New AML Trial: What CLN-049’s Phase 1b Combo Study Could Mean for CGEM InvestorsTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 28, 2026
- Cullinan’s CLN-049 Trial Advances In High-Risk Blood Cancers, Keeping Investor Focus On CGEMTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 28, 2026
- Cullinan’s CLN-978 RA Trial: Early-Stage Catalyst in a Crowded Autoimmune MarketTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 20, 2026
- Cullinan’s CLN-978 RA Trial: Early-Stage Catalyst in a Crowded Autoimmune MarketTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 20, 2026
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CGEM | $9.07 | +0.7% | 998.32K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Cullinan Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW